Publications by authors named "Angela Lax"
Background: The US Department of Veterans Affairs, Department of Defense (VA/DoD) clinical guidelines recommend extended-release naltrexone (XR-NTX) as a treatment option for moderate-to-severe alcohol use disorder (AUD); however, contemporary real-world outcomes related to this guideline are lacking. This retrospective, observational, descriptive study examined treatment patterns and healthcare resource use (HCRU) among veterans with an AUD diagnosis who initiated XR-NTX.
Methods: Veterans with incident AUD who initiated XR-NTX between 8/2014 and 11/2018 were identified.
Article Synopsis
- - The study investigates the impact of prostate-specific antigen doubling time (PSADT) on patients with biochemical recurrence (BCR) of nonmetastatic castration-sensitive prostate cancer (nmCSPC), analyzing data from the Veterans Health Administration between 2006 and 2020.
- - Patients were grouped based on rapid (≤9 months) and less rapid (>9 to ≤15 months) PSADT; rapid PSADT correlated with significantly shorter times to first treatment and worse outcomes in terms of metastasis, metastasis-free survival, and overall survival.
- - The findings suggest that patients with rapid PSADT typically started secondary treatment within a year of BCR, and early treatment appears to yield better outcomes compared to historical data
Chimeric antigen receptor T-cell (CAR-T) infusion settings may impact healthcare resource use (HRU) and reimbursement amounts. Adults with diffuse large B-cell lymphoma receiving CAR-T therapy were identified from the Centers for Medicare & Medicaid Services (CMS) 100% fee-for-service Medicare database and stratified into inpatient (IP; = 380) and outpatient (OP; = 50) cohorts based on CAR-T infusion setting. During the first month post-infusion, OP cohort had significantly fewer IP visits, IP days, intensive care unit (ICU) stays, ICU days, and significantly more OP, emergency room (ER) visits, than IP cohort.
View Article and Find Full Text PDFIntroduction: Chronic hypoparathyroidism is associated with higher risk of developing chronic kidney disease compared with the general population. This study evaluated changes in estimated glomerular filtration rate (eGFR) over a 5-year period in adult patients with chronic hypoparathyroidism treated with recombinant parathyroid hormone (1-84), rhPTH(1-84), compared with a historical control cohort of patients who did not receive rhPTH(1-84).
Methods: This retrospective cohort study included patients with chronic hypoparathyroidism treated with rhPTH(1-84) in the REPLACE (NCT00732615), RELAY (NCT01268098), RACE (NCT01297309), and HEXT (NCT01199614 and continuation study NCT02910466) clinical trials.
Objective: This study assessed the risk of developing chronic kidney disease (CKD) and decline in estimated glomerular filtration rate (eGFR) over a period of up to 5 years in adult patients with chronic hypoparathyroidism treated with recombinant human parathyroid hormone (1-84) (rhPTH[1-84]) compared with a historical control cohort of patients not treated with rhPTH(1-84).
Design: Retrospective cohort study of patients with chronic hypoparathyroidism treated with rhPTH(1-84) derived from the REPLACE (NCT00732615), RELAY (NCT01268098), RACE (NCT01297309) and HEXT (NCT01199614, and its continuation study NCT02910466) clinical trials and a historical control cohort who did not receive PTH selected from an electronic medical record database.
Patients: One hundred and eighteen patients treated with rhPTH(1-84) and 497 patient controls.
Article Synopsis
- Azithromycin, a common antibiotic for respiratory infections, was compared to amoxicillin-clavulanate in terms of cardiovascular and noncardiovascular mortality among US Veterans treated for respiratory or ear-nose-throat infections.
- The study analyzed data from over 790,000 prescriptions and found no significant difference in cardiovascular death risk between azithromycin and amoxicillin-clavulanate within 1-5 days after treatment.
- Overall results indicated no association between either antibiotic and increased cardiovascular mortality, nor any significant difference in noncardiovascular or cardiac death rates.
Objective: To compare treatment patterns of United States (US) veterans stable on innovator infliximab (IFX) who switched to an IFX biosimilar (switchers) or remained on innovator IFX (continuers).
Methods: US Veterans Healthcare Administration data (01/2012-12/2019) were used to identify adults with rheumatoid arthritis (RA), psoriatic arthritis (PsA), plaque psoriasis (PsO), ankylosing spondylitis (AS), or Crohn's disease and ulcerative colitis (i.e.
Background: Limited data are available on the real-world effectiveness and safety of systemic therapies for advanced (surgically unresectable and/or metastatic) epithelioid sarcoma (ES).
Methods: A retrospective medical records review was conducted in patients with advanced ES who were initiating first-line or ≥2 lines of systemic therapy (2000-2017) at 5 US cancer centers. The real-world overall response rate (rwORR), the duration of response (rwDOR), the disease control rate (rwDCR) (defined as stable disease for ≥32 weeks or any duration of response), and progression-free survival (rwPFS) were assessed by radiology reports.